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Abstract
Background: Rapamycin is an immunosuppressive which represses translation of transcripts
harbouring a polypyrimidine motif downstream of the mRNA cap site through the mammalian
target of rapamycin complex. It inhibits the abnormal autologous proliferation of T-cell clones
containing a transcriptionally active human T-lymphotropic virus, type I (HTLV-I) provirus,
generated from infected subjects. We showed previously that this effect is independent of the
polypyrimidine motifs in the viral long terminal repeat (LTR) R region suggesting that HTLV-I
transcription, and not translation, is being affected. Here we studied whether rapamycin is having
an effect on a specific transcription factor pathway. Further, we investigated whether mRNAs
encoding transcription factors involved in HTLV-I transcriptional activation, specifically CREB, Ets
and c-Myb, are implicated in the rapamycin-sensitivity of the HTLV-I LTR.
Results: An in vitro analysis of the role of SRE- and NF-κB-mediated transcription highlighted the
latter as rapamycin sensitive. Over-expression of c-Myb reversed the rapamycin effect.
Conclusion: The sensitivity of HTLV-I transcription to rapamycin may be effected through an NF-
κB-pathway associated with the rapamycin-sensitive mTORC1 cellular signalling network.
Background
The human T-lymphotropic virus, type I (HTLV-I) is the
causative agent of a progressive neurological disorder,
HTLV-I-associated myelopathy/tropical spastic parapare-
sis (HAM/TSP [1,2]) and adult T-cell leukaemia/lym-
phoma (ATLL [3,4]) in addition to a number of other
autoimmune disorders.
HTLV-I-infected primary T-cell clones, derived from
peripheral blood mononuclear cells (PBMC) from HAM/
TSP-affected individuals, can be classified according to
their proliferation capability. Some clones display high
proliferation levels in the absence of exogenous inter-
leukin-2 (IL-2) whereas others do not [5]. This autologous
proliferation, correlates with the presence of a transcrip-
tionally active provirus [5] and is independent of IL-2 and
the IL-2 receptor (IL-2R) [6]. It may contribute to the
development of T-cell malignancy. The ability of the pro-
liferating cells to induce bystander T-cell proliferation in
an IL-2-dependent manner [6] may be an important com-
ponent in the development of HAM/TSP and other HTLV-
I-associated autoimmune diseases. Conceivably, inhibit-
ing this effect might be of value in treating these condi-
tions. A notable feature of the HTLV-I-infected T-cell
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liferation by the immunosuppressant rapamycin
(sirolimus) but not by FK506 (tacrolimus) or
cyclosporine A [5]. FK506, also an immunosuppressive
drug, bears chemical structural similarity to rapamycin
(reviewed in [7]).
The growth inhibitory properties of rapamycin are medi-
ated through the mammalian target of rapamycin
(mTOR) network. mTOR (or FRAP, RAFT, SEP, RAPT [8])
is a member of the phosphatidylinositol kinase-related
kinases (PIKKs), a group of signalling molecules. These
proteins seem to function at a checkpoint for nutritional
status in G1 as well as in response to the phosphatidyli-
nositol 3-kinase (PI3K)-dependent pathway. Of two
mTOR complexes identified, mTORC1 responds to
growth factors via the P13K pathway (reviewed in [9]).
Following stimulation of this pathway by insulin or insu-
lin-like growth factors, a conversion product enables
phosphorylation of Akt. This pathway is linked to
mTORC1 through a heterodimer of the tuberous sclerosis
proteins TSC1 (hamartin) and TSC2 (tuberin), which neg-
atively regulates mTORC1 signalling. TSC2 acts as a
GTPase-activating protein for the Rheb GTPase which has
been proposed to induce conformational change in, and
activation of, mTORC1 thereby enabling phosphorylation
of downstream factors. Akt has been observed to phos-
phorylate and inactivate TSC2 and thus the inactivation of
mTORC1 by the heterodimer is relieved. The mTORC1
multimeric complex regulates a number of pathways
involved in cell mass including protein synthesis, tran-
scription and ribosome biogenesis. One of these func-
tions of mTORC1 is the constitutive phosphorylation of
S6K1 and helicase factors, e.g. the translation inhibitor,
4E-BP1. This process was initially thought to be required
for translation of the 5' polypyrimidine tract (5' TOP)
mRNA species (reviewed in [8]) but the mechanism by
which mTORC1 controls this translation is now less cer-
tain in light of recent reports suggesting that it does not
depend on S6K activity or S6 phosphorylation [10,11].
Cap-dependent translation control may be promoted
through the association of mTORC1 with S6K1 through
translation initiation factor, eIF3 [12].
The repressive effect of rapamycin is mediated through its
formation of inhibitory complexes with cellular immu-
nophilins, the FK506-binding proteins (FKBP). As with
the cyclosporin A-cyclophilin complex, the FK506-
FKBP12 complex interacts with, and inhibits, calcineurin,
which is required for transcriptional activation of IL-2 in
response to T-cell antigen receptor binding. In contrast,
the rapamycin-FKBP12 gain-of-function complex inter-
acts with mTORC1 inhibiting downstream signalling
from mTORC1 by an as yet uncertain mechanism
(reviewed in [9]). Rapamycin was reported to regulate
cap-dependent translation of an increasing number of cel-
lular genes through a mechanism dependent upon the
mRNA possessing a 5' TOP downstream of the cap site
[13-15].
We have previously investigated the nature of the rapamy-
cin sensitivity of the T-cell clones. We have shown that
polypyrimidine motifs present downstream of the HTLV-
I cap site do not contribute to the rapamycin-sensitivity of
the virus [16] raising the possibility that the observed
reduced proliferation of HTLV-I-infected T-cell clones is a
result of sub-optimal viral transcription rather than dys-
regulated translation. Through the mTORC1 network,
rapamycin may down-regulate a pathway linked to trans-
lation of a gene which gives rise to a transcription factor
with HTLV-I LTR binding capability. Alternatively
rapamycin may be inhibiting HTLV-I and T cell prolifera-
tion through independent mechanisms.
HTLV-I transcriptional control is mediated primarily by
the viral trans-activating protein, Tax, which interacts indi-
rectly with the viral 5' long terminal repeat (LTR). This
interaction occurs through complex formation with cellu-
lar transcription factors for which there are binding motifs
in the U3 region. Of the transcription factors involved, the
binding of the cAMP-responsive element-binding protein
(CREB) to core regions of the three 21-bp imperfect
repeats in the U3 region (reviewed in [17]) is central to
efficient viral transcription. Other transcription factors
reported to play a role in viral promoter activity are the
Ets1 and Ets2 proteins [18] and c-Myb proteins. For the
latter there are reported to be both high- and low-affinity
binding sites [19,20]. Ets1 is preferentially expressed in
lymphocytes and is linked to oncogenesis in humans
(reviewed in [21]). The c-myb gene is predominantly
expressed in haematopoietic cells, is involved in the con-
trol of normal cell proliferation, and has been implicated
in the induction of neoplasia (reviewed in [22,23]). c-
Myb has been suggested to initiate viral transcription fol-
lowing integration into the host genome independently of
Tax. Production of the viral Tax protein is thereby enabled
and Tax successfully competes with c-Myb for further
recruitment of CBP [24]. Tax down-regulates the c-myb
promoter [25,26] and may prevent production of further
c-Myb. The trans-activation through formation of a Tax-
CREB-CBP complex at the enhancer elements of the
HTLV-I LTR is essential for highly efficient viral transcrip-
tion [27]. The Tax-independent binding of Ets1 transcrip-
tion factor binding may also be important in early
transcription either from de novo infection or from a latent
provirus [18].
In addition to its direct function in the virus lifecycle, the
mechanistic role of Tax in cellular dysfunction likely
relates to its transactivation of the promoters of severalPage 2 of 9
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shown to dysregulate cellular gene transcription by
exploiting four signalling pathways: CREB/ATF, NF-κB,
SRF, and AP-1.
Our previous studies excluded a direct effect of rapamycin
on HTLV-I mRNA [16] thus in this study we sought to elu-
cidate the rapamycin-sensitive factor and pathway
upstream of HTLV-I transcription which likely impacts on
LTR activity. We hypothesise that a protein involved in
transcriptional control of the virus may itself be regulated
by rapamycin, and potentially forms part of the mTORC1
signalling network. The major protein candidates were
CREB, Ets1 and 2, and c-Myb, through their known inter-
action with the HTLV-I LTR. Since these protein candi-
dates function through the SRE and NF-κB pathways we
investigated the effect of rapamycin on SRE and NF-κB
reporter constructs in transfection experiments: we subse-
quently identified the NF-κB pathway as responsive to
rapamycin. Over-expression of c-Myb was able to counter-
act the rapamycin-induced repression of the wild type
HTLV-I 5' LTR, thereby corroborating the importance of
an NF-κB pathway.
Results and Discussion
Rapamycin affects an NF-κB-dependent pathway
We sought to identify the HTLV-I-associated transcription
factor pathway responsible for the rapamycin-sensitivity.
We have previously shown that a COS-1 cell-based in vitro
system, as well as pilot studies in Jurkat T-cells, sufficiently
mimicked the scenario witnessed in T-cell clones [16],
supporting the use of this in vitro system to further charac-
terise elements of the mechanism of HTLV-I rapamycin-
sensitivity. Here, we established that an NF-κB-responsive
promoter construct was sensitive to rapamycin when co-
transfected into COS-1 with the Tax expressor, whereas
the SRE-responsive promoter construct was not (data not
shown). Since c-myb is predominantly expressed in
hematopoietic cells, the use of COS-1 cells minimises the
levels of endogenous c-Myb present. In transfected COS-1
cells the activity of the NF-κB-responsive promoter con-
struct (2 × 18-CAT) in the presence of Tax was reduced in
the presence of 20–120 nM rapamycin to approximately
65% of the zero rapamycin control (P < 0.002 Student's
paired t test). In contrast, the activity of the SRE-respon-
sive promoter construct (c-fos-SRE-CAT) in the presence of
Tax and 120 nM rapamycin was virtually unchanged at
95% of the zero rapamycin control (P > 0.5 Student's
paired t test; Figure 1). These data suggest that an NF-κB-
responsive pathway is involved in the rapamycin sensitiv-
ity of HTLV-I. Cell number, growth and transfection effi-
ciency were not affected by the presence of rapamycin as
assessed by transient transfection of COS-1 cells with a
GFP expression plasmid (data not shown).
Over-expression of the c-myb gene, but not the CREB or 
Ets1 genes rescues down-regulated promoter activity
We have shown that an NF-κB but not an SRE-responsive
pathway is rapamycin sensitive. Since c-myb expression is
regulated in part through members of the NF-κB tran-
scription factor family [29] this finding suggested a poten-
tial link between c-Myb and HTLV-I provirus sensitivity to
rapamycin. We corroborated our data from the previous
experiment by determining the effect of over-expression
of an NF-κB-specific protein on HTLV-I LTR activity in the
presence of rapamycin. The HTLV-I Tax protein transacti-
vates the c-fos promoter through the serum response ele-
ment (SRE) [30] and the c-myb promoter through an NF-
κB pathway [26]. Tax protein is known to antagonise the
transcriptional activity of c-myb [26]. Neither the tax nor
the c-myb genes in the protein expression constructs
employed in our study are controlled by their native pro-
moters, rather the backbone plasmid, pcDNA3, has the
CMV immediate early promoter (previously determined
as rapamycin-insensitive [16] and Figure 2A) to drive high
expression. This is further illustrated in Figure 2B in which
the level of c-Myb protein does not differ significantly in
the presence of 60 nM rapamycin when compared to the
rapamycin-negative control. This alleviates the problem
of the expressed Tax and c-Myb proteins reciprocally inter-
fering with transcriptional activity.
Co-transfection of neither the Ets1 expression vector,
ΔEBEts1, nor the backbone vector, ΔEBΦ, was able to
restore the rapamycin-induced down-regulation of CR-
CAT (Figure 3A; P > 0.1, Student's paired t test). Co-trans-
fection of the backbone vector, pcDNA3, also did not alter
the rapamycin sensitivity of CR-CAT in the presence of Tax
[16] (Figure 3B) nor did the addition of the CREB expres-
sion construct, pcDNA3CREB, have any effect on this sen-
sitivity. There is a trend to reduction in HTLV-I LTR
activity in the presence of the CREB expression construct
with notably, transfection of a 2 × amount also failing to
rescue the activity of the CR-CAT promoter. In marked
contrast co-transfection of the c-Myb expression con-
struct, pcDNA3-c-myb reversed the rapamycin effect with
evidence of a heightened effect at the 2 × amount (Figure
3B). At the highest rapamycin concentration there is a sig-
nificant difference between the effect of c-Myb and that of
either CREB or pcDNA3 (P < 0.01, Student's paired t test).
U3 deletion mutants and the wild type are comparably 
sensitive to rapamycin and FK506
To determine whether c-Myb is a protein within the NF-
κB transcription pathway that contributes to the decrease
in HTLV-I transcriptional activity in the presence of
rapamycin we generated HTLV-I LTR-CAT constructs from
which sequences corresponding to published c-Myb-
binding motifs in the U3 region were deleted. Similar con-
structs were generated in which CREB- and Ets-bindingPage 3 of 9
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activity in the presence of rapamycin would suggest that
the binding motif of a rapamycin-sensitive protein has
been deleted.
The activities of the wild type promoter and each of the
U3 mutant promoters in the absence and presence of
rapamycin, when co-transfected into COS-1 cells with the
Tax expressor, are illustrated in Figure 4B. Results from at
least three independent experiments (± SEM) are illus-
trated for the control construct, pIEP1-CAT, and the wild
type and deletion constructs. As with the wild type pro-
moter, the activity of each of the deletion mutants in the
presence of three concentrations of rapamycin, 20 nM, 60
nM, and 120 nM, was less than that of the rapamycin-neg-
ative controls. The differences between the activities of
each of the experimental constructs and the control at the
highest concentration of rapamycin are not significant (P
> 0.5, paired Student's paired t test) whereas the values for
pIEP1-CAT and CR-CAT were significantly different (P <
0.05, paired Student's paired t test). CR-CAT is clearly
more susceptible to rapamycin inhibition than pIEP1-
CAT despite the latter having some NF-κB response ele-
ments. This may be a dose effect as the pIEP1-CAT activity
begins to fall slightly at the higher concentrations of
rapamycin.
In microarray and proteomics studies of genes regulated
by rapamycin in T cells [31] the c-myb gene was high-
lighted as being translationally unaffected by rapamycin
as was ELK1, a member of the Ets oncogene family, and
ATF2/CREBP1. We have highlighted the reduction in
available c-Myb as being a potential downstream effect of
translational control by rapamycin, thus factors upstream
in the c-Myb activation pathway are likely candidates for
the site of rapamycin sensitivity. Oh and Reddy review
The effect of rapamycin on an SRE-responsive (c-fos-SRE-CAT) and an NF-κB-responsive construct (2 × 18-CAT), each co-transfected with the pcDNA3Tax/R x c struct, is shownFigur  1
The effect of rapamycin on an SRE-responsive (c-fos-SRE-CAT) and an NF-κB-responsive construct (2 × 18-CAT), each co-
transfected with the pcDNA3Tax/Rex construct, is shown. CAT acetylation values are given as the percentage of the rapamy-
cin-negative control. Mean values of three independent triplicate assays are illustrated ± SEM.
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Interestingly, Grolleau et al. showed that intracellular lev-
els of the Ets2 repressor factor (ERF) mRNA were found to
increase three-fold in rapamycin-treated cells (13). Thus
ERF might sequester the Ets-2 factor available for acting as
a cofactor to c-Myb. Phan and colleagues [32] identified a
rapamycin-sensitive regulator of c-myb expression. CMAT
(c-myb in activated T cells) binds to a region of the c-myb
promoter thereby enhancing expression. Concentrations
of rapamycin in excess of 1 ng/ml prevented the CMAT
complex formation at the promoter seen in the 'no
rapamycin' control. In contrast with the scenario seen in
The effect of over-expression of c-Ets1 (A) and c-Myb and CREB (B) on the promoter activity of CR-CAT in the presence and absenc  of rapamycin is illustratedFigure 3
The effect of over-expression of c-Ets1 (A) and c-Myb and CREB (B) on the promoter activity of CR-CAT in the presence and 
absence of rapamycin is illustrated. CAT acetylation values are given as the percentage of the rapamycin-negative control for 
each construct. Mean values of duplicate independent assays are illustrated ± SEM.
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The activities of the wild type HTLV-I LTR (CR-CAT) and the CMV promoter construct (pIEP1-CAT) in the presence and absen e of rapamycin are illustratedFigure 2
The activities of the wild type HTLV-I LTR (CR-CAT) and the CMV promoter construct (pIEP1-CAT) in the presence and 
absence of rapamycin are illustrated. CAT acetylation values are given as the percentage of the rapamycin-negative control for 
each construct. Mean values of three independent assays are illustrated ± SEM (A). Levels of c-Myb protein from cells grown in 
the presence and absence of rapamycin, as detected in a western blot, are shown. A representative blot of a duplicate experi-
ment is shown (B).
A
0
20
40
60
80
100
120
0 20 60 120
Rapamycin concentration/ nM
%
 
C
A
T 
ac
tiv
ity
 re
la
tiv
e 
to
 r
ap
am
yc
in
-
n
eg
at
iv
e 
co
n
tr
ol
CR-CAT
IEP-CAT
B
c-Myb
Rapamycin/nM 0 20 60Page 5 of 9
(page number not for citation purposes)
Retrovirology 2007, 4:24 http://www.retrovirology.com/content/4/1/24
Page 6 of 9
(page number not for citation purposes)
A. The region deleted in each HTLV-I LTR mutant, with respect to the wild type (CR-CAT) is illustrated schematicallyFigur  4
A. The region deleted in each HTLV-I LTR mutant, with respect to the wild type (CR-CAT) is illustrated schematically. Basal 
and Tax-trans-activated promoter activity for each mutant is shown compared to the wild type. Absolute CAT acetylation val-
ues are given. B. The activities of the wild type HTLV-I LTR and the deletion mutant HTLV-I LTRs in the presence and absence 
of rapamycin are illustrated. CAT acetylation values are given as the percentage of the rapamycin-negative control for each 
construct. Mean values of three independent assays are illustrated ± SEM.
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Retrovirology 2007, 4:24 http://www.retrovirology.com/content/4/1/24the HTLV-I-infected T-cell clones, however, the authors
demonstrated that cyclosporin A had the same effect as
did rapamycin on c-myb promoter activity.
More recently, rapamycin has been reported to repress
replication of HIV-1 [33]. In the same manner as we have
previously reported for HTLV-I, the repression was
reversed by FK506 [16]. The authors proposed that the
point of action of rapamycin in the HIV-1 lifecycle is tran-
scription.
Conclusion
In conclusion we have identified an NF-κB-associated
pathway of HTLV-I activation as being sensitive to the
presence of rapamycin: repression of this pathway can be
alleviated by expression of c-Myb protein. Tax is reported
to repress c-Myb gene expression thereby enabling effi-
cient Tax-driven viral expression, thus our observations
highlight that the mechanism for the rapamycin-sensitiv-
ity of HTLV-I-infected T-cell clones is likely to be an
upstream component of the NF-κB pathway. A reduction
of c-Myb cellular levels is known to block T cells in late G1
of the cell cycle [34] however, from the deletion mutant
studies it is difficult to construct a direct link between Myb
over-expression counteracting the rapamycin inhibition
of transcription and the lack of effect of the Myb response
element deletion since Tax and Myb to some extent com-
pete in activating HTLV-I. It seems most likely that
rapamycin is inhibiting HTLV transcription through an
mTORC1-related NF-κB pathway, and in the T cell clones
inhibiting the abnormal proliferation of the cells through
a second, possibly also mTORC1-related, NF-κB regulated
pathway. In the absence of rapamycin it is highly likely
that the latter is responsive to the viral Tax protein.
Of note, it has been reported that induction of c-myb
expression can be inhibited through blocking of the PI3K
pathway [35]. In combination with our data this observa-
tion would suggest that the translational control of the c-
myb mRNA is linked to the PI3K-mTORC1 pathway and
thus repressible by rapamycin. The specificity of this path-
way, which is clearly distinct from Cyclosporin-A medi-
ated effects on T cell proliferation, highlights the
involvement of the specific intracellular immunophilin
pathway and merits serious further investigation as it
would appear to be a novel route for virus induced cell
proliferation which may be a target for prevention of virus
induced neoplasia.
Methods
pcDNA3-CREB construction
The rat CREB expression cassette in plasmid T7βCR1 was
removed using HindIII and EcoRI and cloned into identi-
cal sites of pcDNA3 (Invitrogen). Correct cloning was
identified by sequencing.
Construction of U3 deletion mutants
Plasmid CR-CAT comprises the U3, R and the 5' region of
U5 of HTLV-I, and has been described previously [36].
The sequence of the U3 through the U3-R boundary
region is illustrated (Figure 1). CR-CAT was subjected to
PCR mutagenesis using Pfu DNA polymerase (Strata-
gene). Sequence flanking the region to be deleted was
amplified using opposing oligonucleotides. A 10 ng
amount of plasmid was amplified in a 50 μl reaction vol-
ume comprising 1 × native reaction buffer (Stratagene),
3.5–5 μM MgCl2 (depending on primer pair), 0.25 mM
each dNTP, 0.12 μM each oligonucleotide and 0.02 units
Pfu DNA polymerase. A single incubation of 96°C for 45
s was followed by 30 cycles comprising 96°C for 45 s,
37°C for 45 s and 72°C for 10 min and an additional sin-
gle extension step at 72°C for 10 min Oligonucleotides
used to generate CR(ΔEI)-CAT were IR (5'tta gag gcc tCA
GAC TTC TGT TTC TCG G3') and IF (5'gta gcg ata tcA GCA
CCG GCT CGG G3'); CR(ΔEII)-CAT were IIR (5'tta gag gcc
tCC GGG GGG AGA CGT CAG AGC C3') and IIF (5'tag
cga tat cAT AAG CTC AGA CCT CC3'); CR(ΔEIII)-CAT
were IIIR (5'gca tag gcc tTT GAC AAA CAT GG 3') and IIIF
(5'gta gcg ata tcG GCA CGC ATA TGG C3'); CR(ΔEts)-CAT
were EtsR (5'tta gag gcc tTA TGA TTT GTC TTC AG3') and
EtsF (5'gta gcg ata tcC GTC CTC AGG CGT TG3');
CR(ΔMyb)-CAT were MybR (5'tta gag gcc tTT TAT AGA
CTC CTG3') and MybF (5'gta gcg ata tcG GGG CTC GCA
TCT CTC C3'); where sequences in upper case are comple-
mentary to HTLV-I LTR sequence, those in italicised low-
ercase introduce a StuI (IR, IIR, IIIR, EtsR, MybR) or an
EcoRV (IF, IIF, IIIF, EtsF, MybF) restriction site, and those
in plain lowercase represent random sequence. Gel puri-
fied amplicon was restricted with StuI and EcoRV and cir-
cularised using a Rapid Ligase kit (Boehringer Mannhein).
The primers designed to remove the high-affinity c-Myb
binding motif were designed to retain the TATA box and
the U3-R boundary. Correct deletions were confirmed by
sequencing.
Transient transfections
To assess the activity of the NF-κB and SRE-responsive
reporter constructs: 5 μg of each plasmid (2 × 18-CAT or
c-fos-SRE-CAT, respectively) were transiently transfected
with an equal amount of pcDNA3Tax/Rex into 5-cm
diameter tissue culture dishes seeded with 0.6 × 106 COS-
1 cells 16 h previously, using the DEAE-dextran method
[37]. Briefly, cells were washed with 1 × phosphate buff-
ered saline (PBS) and plasmid and 50 μl DEAE-dextran
(10 mg/ml in 1 M Tris-HCl; pH 7.4) was added in 1 ml
PBS. Following a 30 min incubation at 37°C with 5%
CO2, 3.5 ml DMEM (Invitrogen) supplemented with 80
μM chloroquine was added. Following incubation for a
further 2.5 h cells were incubated with 10% (w/v) DMSO
in DMEM for 2 min, washed with DMEM and resus-
pended in DMEM media supplemented with 10% fetalPage 7 of 9
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bated for 24 h at 37°C with 5% CO2.
To assess the effect of over-expressed protein on wild type
HTLV-I LTR activity in the presence of rapamycin: co-
transfection of 250 ng transcription factor expression plas-
mids was performed with an equal amount of CR-CAT
and pcDNA3Tax/Rex in COS-1 cells as above.
To assess the HTLV-I LTR deletion mutants: 1 μg each CR-
CAT deletion mutant was either transiently transfected
alone or co-transfected, with 1 μg pcDNA3Tax/Rex
(HTLV-I Tax expression vector), as above.
When required, rapamycin (Sigma) was added to the
post-transfection culture medium at a final concentration
of 0, 20, 60 or 120 nM. FK506 (Calbiochem) was added
to a final concentration of 2 μM either alone or in combi-
nation with rapamycin.
For all transfection experiments, the levels of CAT acetyla-
tion products in 30 μl cell supernatant were assessed 24 h
post-transfection by thin-layer chromatography, quanti-
fied on an Instant Imager (Canberra Packard) and
expressed either as absolute acetylation values or as a per-
centage of the levels of CAT acetylation of the rapamycin-
negative control.
Western blot analysis
To assess the levels of expressed protein in the presence of
rapamycin (0–60 nM range), transfections were carried
out as above with each expression plasmid. Total cellular
protein from 1 × 106 COS-1 cells transfected with
pcDNA3-c-myb was harvested and 1/20 vol. blotted onto
a nitrocellulose membrane using standard techniques.
The primary antibody was a rabbit anti-c-Myb polyclonal
antibody at a 1:500 dilution; the secondary goat anti-
monkey horseradish peroxidase-linked antibody was
applied at a 1:1000 dilution. Proteins were detected using
ECL reagents (Amersham), according to the manufac-
turer's instructions, followed by autoradiography.
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